Efficacy of Dupilumab (Dupixent^®) in the treatment of chronic rhinosinusitis with nasal polyps: First results from Hamburg

Introduction The launch of Dupilumab is the first targeted systemic treatment option approved in Germany since October 2019 for severe chronic rhinosinusitis with polyposis nasi (CRSwNP). The aim of this study is to compare and evaluate the parameters necessary for indication and monitoring of Dupilumab in patients treated with Dupilumab in our clinic in 2019 and 2020 in order to better assess the effect of the therapy.

Material and methods Since October 2019, we used dupilumab therapy in 18 patients (8 male, 10 female). The following parameters were assessed: the Sinonasal Outcome Test-22, the forced expratory pressure in 1 second, the olfactometry, a visual analog scala of the total complaints, the Nasal Polyp Score as well as total IgE, eosinophilic cationic protein and eosinophils.

Results The average age was 48.4 (SD ± 17.4). The follow-up period was 6 months. The SNOT-22 average was 68 (±15.1) at the first visit, 29.1 (±13.4) after 3 months and 24.7 (±11.6) after 6 months. The NPS was 4.46 (± 1.39), after 3 months 1.86 (±0.37) and after 6 months 1.8 (±0.45). Olfactometry showed 3.62 (±3.99) at the baseline, 8.67 (± 2.42) after 3 months and 9.17 (±2.14) after 6 months. The other parameters also improved over time.

Conclusion Under Dupilumab therapy, there was a significant improvement of medical findings and symptoms in all categories mentioned, as well as a significant reduction in the necessitiy for systemic glucocorticoids and for re-surgery. Dupilumab is therefore a good therapy alternative for severe CRSwNP.

Poster-PDF A-1448.pdf

Conflict of interest

Der Erstautor gibt keinen Interessenskonflikt an.

Publication History

Article published online:
13 May 2021